ReviewReviews in cardiovascular medicine2026
Cardiovascular-Kidney-Metabolic Syndrome: Models of Care.
Review in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular-kidney-metabolic (CKM) syndrome represents the complex interplay between cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic disorders such as type 2 diabetes and obesity. These conditions share overlapping risk factors, pathophysiological mechanisms, and clinical outcomes, leading to progressive organ dysfunction, as well as increased morbidity and mortality. Traditional disease-specific care models, in which cardiology, nephrology, and endocrinology operate in separate clinics, are increasingly inadequate for addressing the integrated nature of CKM syndrome. Patients often experience fragmented care, with different specialties prioritizing different medications and communicating slowly via letters, which delays important guideline-directed medical therapy (GDMT) for each organ system, potentially leading to higher rates of hospital admissions and mortality. New models of care are urgently needed to improve outcomes through coordinated, patient-centered, and multidisciplinary approaches. Future integrated CKM care models should emphasize cross-specialty collaboration, data sharing, and shared decision-making to optimize treatment and deliver comprehensive care plans that consider all three specialty domains. Advances in digital health, precision medicine, and population health analytics can support these models by enabling more accurate risk stratification, personalized interventions, and continuous monitoring across the care continuum. This review, originating from an International Society of Nephrology Transplant Sister Center Meeting, synthesizes the available evidence on multispecialty clinics and other interventions designed to improve care for patients with multiple CKM comorbidities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.